References
- Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy. 2004;59:869–873.
- Barbosa F, Freitas J, Barbosa A. Chronic idiopathic urticaria and anxiety symptoms. J Health Psychol. 2011;16:1038–1047.
- Barbosa F, Freitas J, Barbosa A. Alexithymia in chronic urticaria patients. Psychol Health Med. 2011;16:215–224.
- Bernstein J, Lang D, Khan D, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133:1270–1272.
- Rutkowski K, Grattan C. How to manage chronic urticaria 'beyond' guidelines: a practical algorithm. Clin Exp Allergy. 2017;47:710–718.
- Maurer M, Rosen K, Hsieh H, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013; 368:924–935.
- Gomez G, Jogie-Brahim S, Shima M, et al. Omalizumab reverses the phenotypic and functional effects of IgE-enhanced FcεRI on human skin mast cells. J Immunol. 2007;179:1353–1361.
- Eckman J, Sterba P, Kelly D, et al. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol. 2010;125:889–895.
- Bernstein J, Kavati A, Tharp M, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidence. Exp Opin Biol Ther. 2018;18:425–448.
- Goldstein S, Gabriel S, Kianifard F, et al. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: review of omalizumab clinical trials. Ann Allergy Asthma Immunol. 2017;118:500–504.